June 2016
Stockmarket rock stars whose funds stand out from the crowd
Five fund managers who are star performers and how they got there.
- Updated
- James Frost
January 2016
Biotech stocks to get the heart racing … or slowing
Notoriously volatile and tricky to pick, biotechnology stocks gave nimble investors plenty of opportunity to outperform blue chips in 2015 and are set to provide some wild rides in 2016 too.
- Updated
- Jessica Sier
December 2014
The biggest biotechnology blunders of 2014
Biotechnology investors understand that their appetite for speculation brings both risk and reward, but it is likely that even the bravest stockpickers will be happy to leave 2014 behind.
- Updated
- Jessica Gardner
October 2014
GI Dynamics falls 50pc on product suspension
GI Dynamics investors aren’t waiting to see whether it can survive a suspension in sales of its main product to treat type 2 diabetes as the medical device maker’s shares fell 50 per cent.
- Updated
- Jessica Gardner
GI Dynamics falls 50pc on product suspension
GI Dynamics investors aren’t waiting to see whether it can survive a suspension in sales of its main product to treat type 2 diabetes as the medical device maker’s shares fell 50 per cent.
- Updated
- Jessica Gardner
August 2014
GI Dynamics (GID)
CIMB has an “add” recommendation on GI Dynamics and a $1.04 target price.
- Updated
- Will Willitts
July 2013
GI Dynamics placement upsized to $57.5 million
GI Dynamics’ placement of CHESS Depository Interests (CDIs) has been upscaled to $57.5 million from $35 million due to strong demand from local and domestic fund managers, sources told Street Talk Online on Wednesday.
- Updated
- Sarah Thompson | Anthony Macdonald | Gretchen Friemann
2013 a tough year for small caps
The past 12 months have been a miserable affair for many small caps, with the index now trading at its lowest point since April 2009.
- Updated
- Sally Rose
January 2013
- Opinion
- Opinion
San Fran pharma conference breeds deals
The JP Morgan Healthcare Conference in San Francisco currently underway is the biggest speed-dating event on the biotech calendar each year.
- Sarah Thompson and Anthony Macdonald
March 2012
- Opinion
- Opinion
Bell Potter busy with dynamic trades
Bell Potter is understood to have handled trading in 25 million GI Dynamics securities on Wednesday, worth 8.5 per cent of the company.
- Updated
- ANTHONY MACDONALD | STEPHEN SHORE
ResMed competitor likely to list
ResMed may have a new competitor on the Australian Securities Exchange, with US-based Ventus Medical understood to be exploring a listing in Australia.
- Updated
- ANTHONY MACDONALD
January 2012
Healthy deals in San Francisco
It was at a chance meeting between some health industry heavy hitters in San Francisco this time last year that GI Dynamics decided to list in Australia, and the deal makers are back in the States this week.
- Stephen Shore and anthony macdonald
December 2011
Float review: no survivors
Successful sharemarket floats were few and far between in the wreckage that was 2011. So what does that mean for 2012?
- Updated
- Tony Featherstone